Clinical Trial Update: MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine [Phase 4]

View source ↗

Summary

A Phase 4 trial update reports the completed status of a study using MF59-adjuvanted influenza vaccine in combination with the 23-valent pneumococcal polysaccha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)
• MF59-adjuvanted influenza vaccine (influenza vaccine adjuvanted with MF59)

Snippet

Sponsor: Korea University Guro Hospital | Conditions: Influenza, Human, Pneumococcal Infections | Phase 4 | Status: COMPLETED